Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zampilimab (CHF10067) Phase Ib in IPF
NCT05513950Phase 1Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial of Zampilimab in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Subjects With Adverse Event (AE); Non-Serious AEs and Serious AEs at Day 84. Started Jan 2023; status: completed.
02
Drugs
Zampilimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05513950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513950.